NCT07237269 2026-04-15
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
Phase 2 Recruiting
Clinical Trials
51 trialsNCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06244004 2026-03-30
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
Phase 2 Recruiting
NCT07476677 2026-03-17
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT04748042 2026-03-06
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT05726292 2026-03-04
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
University of Chicago
Phase 2 Recruiting
NCT05676463 2026-03-03
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07393867 2026-02-06
ARPEGGIO
Brigham and Women's Hospital
Phase 2 Not yet recruiting
NCT07202247 2026-02-04
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT05568550 2026-01-30
Pembro With Radiation With or Without Olaparib
University of Kentucky
Phase 2 Recruiting
NCT04267887 2026-01-20
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT07313241 2025-12-31
(RANGER)
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT07310433 2025-12-30
Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer
The University of Hong Kong
Phase 2 Not yet recruiting
NCT07268794 2025-12-08
CONVERT-HB1
Fudan University
Phase 2 Not yet recruiting
NCT06150417 2025-11-12
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT05100472 2025-11-04
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05171387 2025-06-22
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
Phase 2 Completed
NCT06392295 2025-06-15
OCEAN
University of Miami
Phase 2 Recruiting
NCT05790213 2025-06-12
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
University of Chicago
Phase 2 Recruiting
NCT06312670 2025-05-29
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT06992232 2025-05-28
Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT06765954 2025-05-06
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
ImmunityBio, Inc.
Phase 2 Not yet recruiting
NCT06212583 2025-05-01
KNIGHTS
University of Maryland, Baltimore
Phase 2 Recruiting
NCT04298983 2025-03-19
RAD 1805
University of Alabama at Birmingham
Phase 2 Terminated
NCT06582446 2025-03-11
HypoElect
German Oncology Center, Cyprus
Phase 2 Recruiting
NCT06818682 2025-02-21
RELAX
Tata Memorial Centre
Phase 2 Recruiting
NCT06772441 2025-01-13
HypoPro
German Oncology Center, Cyprus
Phase 2 Recruiting
NCT03569241 2024-12-09
STORM
University Hospital, Ghent
Phase 2 Active not recruiting
NCT05404139 2024-11-25
DIRECT
University Health Network, Toronto
Phase 2 Recruiting
NCT06500247 2024-07-15
Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.
Qilu Hospital of Shandong University
Phase 2 Not yet recruiting
NCT04465500 2024-05-13
Prostate005
University of Virginia
Phase 2 Recruiting
NCT06305832 2024-03-12
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05851547 2024-01-05
DEFINE
Ottawa Hospital Research Institute
Phase 2 Recruiting
NCT05223582 2023-12-08
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
Fudan University
Phase 2 Unknown
NCT03649841 2023-10-26
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
Phase 2 Terminated
NCT05778097 2023-03-21
ARES
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT05753566 2023-03-06
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05717582 2023-02-08
CHAMPION
Fudan University
Phase 2 Not yet recruiting
NCT03845751 2023-01-12
ENHANCE
Institut Mutualiste Montsouris
Phase 2 Unknown
NCT05249712 2023-01-03
Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT03061643 2022-03-08
An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
Samsung Medical Center
Phase 2 Unknown
NCT04489745 2020-07-28
Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
VA Greater Los Angeles Healthcare System
Phase 2 Unknown
NCT03827473 2020-06-25
ACADEMIC
University of Utah
Phase 2 Terminated
NCT02217566 2020-01-13
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Janssen Research & Development, LLC
Phase 2 Completed
NCT00283803 2018-08-07
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Phase 2 Completed
NCT00776594 2016-10-21
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00006359 2016-07-18
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00521781 2016-03-17
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT00003517 2013-07-10
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn